Boston Scientific's cyberattack delays Q3 revenue but impact may be temporary, shares valued below fair price.

Boston Scientific experienced a cyberattack that will negatively affect its third-quarter results, primarily causing delays in revenue rather than permanent losses due to quick recovery in manufacturing and shipping. However, concerns remain about the WATCHMAN device and U.S. electrophysiology markets, which were already slowing before the attack, as well as increased debt from acquiring Penumbra. The company's shares currently trade at about 13 times the withdrawn earnings forecast, with an estimated fair value of $55, suggesting potential for buying without expecting immediate growth recovery.